Biora Therapeutics (NASDAQ:BIOR) reported quarterly losses From Continuing Operations of $(6.08) per share which missed the analyst consensus estimate of $(3.85) by 57.92 percent. The company reported quarterly sales of $32.00 thousand which missed the analyst consensus estimate of $210.00 thousand by 84.76 percent.
Biora Therapeutics Q3 2024 GAAP EPS From Continuing Operations $(6.08) May Not Be Comparable To $(3.85) Estimate, Sales $32.00K Miss $210.00K Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated